Abstract
Today there are 140 million people with diabetes worldwide and 90% of them has Type 2 diabetes. The numbers are increasing rapidly and the forecast for 2025 will be over 300 million people with diabetes [1]. Since cardiovascular diseases (CVD) are the major cause of mortality in people with Type 2 diabetes this epidemic of diabetes will undeniably be followed by a wave of CVD globally. To relieve this burden of diabetes we need aggressive actions to prevent diabetes and its complications, particularly CVD. Unfortunately drug therapy to treat type 2 diabetes has improved very little over the last 10–20 years. Therefore the arrival of thiazolidinediones (TZDs, glitazones) that represent a new class of drugs targeting directly insulin resistance, a fundamental feature of Type 2 diabetes, opened a new avenue for the management of diabetes and raised great hopes for a better future [2]. This review aims to answer the challenging question “Are glitazones superior to the standard therapy in the treatment of Type 2 diabetes?”
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025. Diabetes Care 1998; 21:1414–31.
Schoonjans K, Auwerx J. Thiazolidinediones: An update. Lancet 2000;355:1008–10.
Turner RC, Cull CA, Frighi V, Holman RR for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 2000;281:2005–12.
DeFronzo RA. Pharmacological therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281–303.
Matthaei S, Stumvoll M, Kellerer M, Häring H-U. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 2000;21:585–618.
Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL and the Pioglitazone 001 Study Group. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. Diabetes Care 2000;23:1605–11.
Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000;43:278–84.
Buse JB: Pioglitazone in the treatment of type 2 diabetes mellitus: U.S. clinical experience. Exp Clin Endocrinol Diabetes 2000;108(Suppl.2):S250–5.
Goldstein BJ. Rosiglitazone. Int J Clin Pract 2000;54:333–37.
Horton ES, Whitehouse F, Ghazzi MN, Venable TC and the Troglitazone Study Group, Whitcomb RW. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. Diabetes Care 1998;21:1462–69.
Rosenstock J for the Pioglitazone 001 Study Group. Improved sensitivity and beta cell responsivity suggested by HOMA analysis of pioglitazone therapy. IDF 2000, poster P299.
Kipnes M, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with diabetes mellitus: A randomized, placebo-controlled study. Am J Med 2001;111:10–7.
DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;313:541–49.
Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998;338:867-72.
Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. JAMA 2000;283:1695-702.
Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000;22: 1395–409.
Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001;24:758-67.
Schwartz S, Raskin P, Fonseca V, Graveline JF for the Troglitazone and Exogenous Insulin Study Group. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 1998;338:861-66.
Raskin P, Dole JF, Rappaport EB. Rosiglitazone improves glycemic control in poorly controlled, insulin-treated type 2 diabetes. Diabetes 1999;48:A94.
Rubin C, Egan J, Schneider R, on behalf of the Pioglitazone 014 Study Group. Combination therapy with pioglitazone and insulin in patients with type 2 diabetes. Diabetes 1999;48:A110.
Yki-Järvinen H, Ryysy L, Nikkilä K, Tulokas T, Vanamo R, Heikkilä M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. Ann Intern Med 1999;130:389–96.
Glass CK. Antiatherogenic effects of thiazolidinediones? Arterioscler Thromb Vasc Biol 2001; 21:295–96.
Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee T, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;134:61–71.
Tack CJJ, Smits P, Demacker PNM, Stalenhoef AFH. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 1998;21:796–69.
Belcher G, Matthews DR. Safety and tolerability of pioglitazone. Exp Clin Endocrinol Diabetes 2000;108(Suppl.2):S267–73.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Taskinen, MR. (2002). Are Thiazolidinediones Superior to Standard Therapy in the Treatment of Type 2 Diabetes?. In: Fruchart, JC., Gotto, A.M., Paoletti, R., Staels, B., Catapano, A.L. (eds) Peroxisome Proliferator Activated Receptors: From Basic Science to Clinical Applications. Medical Science Symposia Series, vol 18. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1171-7_21
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1171-7_21
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5427-7
Online ISBN: 978-1-4615-1171-7
eBook Packages: Springer Book Archive